IRF1-IN-2
Based on 1 publication(s) in Google Scholar
IRF1-IN-2 (Compound I-19) is an IRF1 inhibitor. IRF1-IN-2 decreases the recruitment of IRF1 to the promoter of CASP1. IRF1-IN-2 inhibits cell death signaling pathway (i.e., cleavage of Caspase 1, GSDMD, IL-1 and PARP1; inhibits the Pho of TKB1, upregulates GPX4 and downregulates FACL4). IRF1-IN-2 has a protective effect on ionizing radiation-induced inflammatory skin injury.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.83%
- CAS No.: 708245-32-3
- 화학식: C18H20N2O4S
- 분자량:360.43
-
보관:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) IRF1-IN-2
MoreAll Caspase Isoforms
More
Biological Activity
제품 설명
IC50 & Target
[1]|
PARP-1 |
GPX4 |
IL-1 |
Caspase-1 |
In Vitro
IRF1-IN-2 pretreatment (20 μM, 12 h) decreases the recruitment of IRF1 to the promoter of CASP1 in irradiated HaCaT cells (20 Gy)[1].
IRF1-IN-2 (20 μM, 24 h) attenuates the NSP-10 plasmid transfection-induced IRF1 activation in HELF and WS1 cells[1].
IRF1-IN-2 protects A375 cells against radiation (20 Gy)[1].
IRF1-IN-2 inhibits cell death signaling pathways, including inhibition of cleavage for Caspase 1, GSDMD, IL-1 and PARP1, phosphorylation of TKB1, up-regulation of GPX4 and down-regulation of FACL4[1].
IRF1-IN-2 maintains mitochondrial activity and ROS production in skin cells in the early stage after irradiation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Radiogenic skin injury mice (intraperitoneal injection of pentobarbital sodium (1%, 30 mg/kg), 35 Gy at the dose rate of 1000 cGy/min by a 6-MeV electron beam)[1]
-
Dosage:100 μg/d
-
Administration:Subcutaneous injection (s.c.), one every other day before irradiation, pretreatment
-
Result:Showed a significant reduction in acute skin inflammatory manifestations, such as erythema and exudation.
Showed protective effects on the function and structural integrity of radiation-induced lesions to the claws.
Chemical Information
-
CAS No. 708245-32-3
-
Appearance Solid
-
분자량 360.43
-
화학식 C18H20N2O4S
-
Color White to off-white
-
SMILES
O=C(NC1=CC=C(S(=O)(N2CCCC2)=O)C=C1)C3=CC=CC=C3OC
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Antioxidants (Basel)
Alpha-Lipoic Acid Inhibits IFN-γ-Induced PD-L1 Expression in Prostate Cancer Cells and Enhances T-Cell-Mediated Anti-Tumor Cytotoxicity. [Abstract]2026 Mar 25;15(4):413. PMID: 42072056
용액&용해도
In Vitro:
DMSO : 125 mg/mL (346.81 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocol
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
순도&문서
-
Data Sheet (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7745 mL | 13.8723 mL | 27.7446 mL | 69.3616 mL |
| 5 mM | 0.5549 mL | 2.7745 mL | 5.5489 mL | 13.8723 mL | |
| 10 mM | 0.2774 mL | 1.3872 mL | 2.7745 mL | 6.9362 mL | |
| 15 mM | 0.1850 mL | 0.9248 mL | 1.8496 mL | 4.6241 mL | |
| 20 mM | 0.1387 mL | 0.6936 mL | 1.3872 mL | 3.4681 mL | |
| 25 mM | 0.1110 mL | 0.5549 mL | 1.1098 mL | 2.7745 mL | |
| 30 mM | 0.0925 mL | 0.4624 mL | 0.9248 mL | 2.3121 mL | |
| 40 mM | 0.0694 mL | 0.3468 mL | 0.6936 mL | 1.7340 mL | |
| 50 mM | 0.0555 mL | 0.2774 mL | 0.5549 mL | 1.3872 mL | |
| 60 mM | 0.0462 mL | 0.2312 mL | 0.4624 mL | 1.1560 mL | |
| 80 mM | 0.0347 mL | 0.1734 mL | 0.3468 mL | 0.8670 mL | |
| 100 mM | 0.0277 mL | 0.1387 mL | 0.2774 mL | 0.6936 mL |